Similarly, Nestor et al. compared ALT-801 (another dual GLP-1/GCG receptor agonist), semaglutide and elafibranor in AMLN diet NAFLD mouse model to validate the beneficial effects of GLP-1/GCG dual agonism in NAFLD hepatic outcomes. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.